Amgen, Inc. (AMGN) Shares Sold by Strategic Advisors LLC

Share on StockTwits

Strategic Advisors LLC reduced its stake in Amgen, Inc. (NASDAQ:AMGN) by 26.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,860 shares of the medical research company’s stock after selling 666 shares during the period. Strategic Advisors LLC’s holdings in Amgen were worth $386,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Fiduciary Group LLC raised its holdings in shares of Amgen by 3.8% in the 3rd quarter. Fiduciary Group LLC now owns 20,881 shares of the medical research company’s stock worth $4,328,000 after purchasing an additional 763 shares in the last quarter. Tompkins Financial Corp raised its holdings in shares of Amgen by 2.7% in the 3rd quarter. Tompkins Financial Corp now owns 19,216 shares of the medical research company’s stock worth $3,983,000 after purchasing an additional 500 shares in the last quarter. Bowling Portfolio Management LLC raised its holdings in shares of Amgen by 3.5% in the 3rd quarter. Bowling Portfolio Management LLC now owns 34,675 shares of the medical research company’s stock worth $7,188,000 after purchasing an additional 1,167 shares in the last quarter. IMA Wealth Inc. raised its holdings in shares of Amgen by 3.3% in the 3rd quarter. IMA Wealth Inc. now owns 10,596 shares of the medical research company’s stock worth $2,196,000 after purchasing an additional 340 shares in the last quarter. Finally, Aperio Group LLC raised its holdings in shares of Amgen by 2.6% in the 3rd quarter. Aperio Group LLC now owns 481,640 shares of the medical research company’s stock worth $99,839,000 after purchasing an additional 12,311 shares in the last quarter. 82.38% of the stock is owned by institutional investors.

AMGN stock opened at $201.80 on Friday. Amgen, Inc. has a 52-week low of $163.31 and a 52-week high of $210.19. The company has a current ratio of 3.39, a quick ratio of 3.12 and a debt-to-equity ratio of 2.03. The company has a market cap of $130.62 billion, a PE ratio of 14.99, a PEG ratio of 1.96 and a beta of 1.40.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, July 26th. The medical research company reported $3.83 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.52 by $0.31. Amgen had a net margin of 10.19% and a return on equity of 43.18%. The business had revenue of $6.06 billion for the quarter, compared to analyst estimates of $5.73 billion. During the same quarter in the previous year, the business earned $3.27 earnings per share. The firm’s revenue was up 4.3% compared to the same quarter last year. Equities research analysts anticipate that Amgen, Inc. will post 14.02 EPS for the current fiscal year.

A number of research firms recently commented on AMGN. Oppenheimer reiterated a “buy” rating and issued a $224.00 target price on shares of Amgen in a report on Tuesday, October 2nd. Jefferies Financial Group reiterated a “buy” rating and issued a $220.00 target price on shares of Amgen in a report on Friday, August 24th. Morgan Stanley boosted their target price on shares of Amgen from $210.00 to $212.00 and gave the stock an “overweight” rating in a report on Thursday, October 11th. Leerink Swann set a $209.00 target price on shares of Amgen and gave the stock a “hold” rating in a report on Monday, September 17th. Finally, Cantor Fitzgerald set a $223.00 target price on shares of Amgen and gave the stock a “neutral” rating in a report on Monday, October 8th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $204.90.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Further Reading: Buyback For Investors Defined

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply